Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

41.15
+0.33000.81%
Volume:633.70K
Turnover:25.97M
Market Cap:29.73B
PE:-87.55
High:41.33
Open:40.64
Low:40.44
Close:40.82
52wk High:42.50
52wk Low:13.81
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.40
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:7.03
PE(LYR):-76.20

Loading ...

Roivant President, CIO Mayukh Sukhatme Disposes of USD 24.12 Million in Common Shares

Reuters
·
Aug 19

Roivant Sciences (ROIV) Receives a Buy from Jefferies

TIPRANKS
·
Aug 18

Citi Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
Aug 10

Roivant Sciences Ltd : Citigroup Raises Target Price to $46 from $42

THOMSON REUTERS
·
Aug 10

Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
Aug 07

Roivant Sciences is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Roivant Sciences price target raised to $42 from $36 at Guggenheim

TIPRANKS
·
Aug 07

Roivant Sciences Ltd : TD Cowen Raises Target Price to $50 from $41

THOMSON REUTERS
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 07

Roivant Sciences Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Stock Track | Roivant Sciences Plunges 5.55% in pre-market After Q1 Loss Widens, Misses Estimates

Stock Track
·
Aug 06

Roivant Sciences' Fiscal Q1 Net Loss Narrows, Revenue Declines

MT Newswires Live
·
Aug 06

Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million

Reuters
·
Aug 06

Earnings Flash (ROIV) Roivant Posts Fiscal Q1 Net Loss $0.26 a Share, vs. FactSet Est of $0.33 Loss

MT Newswires Live
·
Aug 06

Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Benzinga Earnings
·
Aug 06

Roivant Unit Priovant Begins Phase 3 Beacon+ Trial of Brepocitinib in Cutaneous Sarcoidosis

Reuters
·
Aug 06

Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million

Reuters
·
Aug 06

Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 Million

Reuters
·
Aug 06

Roivant Sciences - Brepocitinib Nda Approval and Launch in Dermatomyositis Expected by End of September 2026

THOMSON REUTERS
·
Aug 06